ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1841

To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis

María Paula Álvarez Hernández1, Alfredo Madrid-García2, Alejandro Gómez Gómez3, Lara Borrego Sanz4, Rosalía Méndez Fernández4, Pedro Arriola Villalobos4, Esperanza Pato Cour5, David Díaz Valle4 and Luis Rodriguez-Rodriguez5, 1Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, Madrid, Spain, 3Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, 4Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, 5Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, comparative effectiveness, Disease-Modifying Antirheumatic Drugs (Dmards)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster III

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Non-infectious uveitides (NIUs) include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed in monotherapy or in combination. Several observational studies showed that the use of ISDs in combination could be more effective than their use in monotherapy. However, a direct comparison between these two treatment strategies has not been carried out yet.Objective:To analyze the effect of ISDs combination therapy (CT) on the response rate in patients with NIUs.

Methods: Patients attending a Uveitis Outpatient Clinic from a tertiary care center in Madrid, Spain, and prescribed with ISDs from 1991 to 2018 were included. Patients were assigned as controls or cases based on whether they were prescribed with ISDs in monotherapy (MT) or CT. ISD treatment changes during the observation period were also considered. The primary outcome was good therapeutic response (GTR), defined as the complete resolution of the eye inflammatory manifestations and oral corticosteroid dosage ≤10 mg of prednisone equivalent a day. Furthermore, this situation had to be maintained in at least two consecutive visits spanned at least 28 days. Several propensity score based and non-based weighting techniques for data balancing, followed by Cox regressions, were performed to estimate the effect of CT on the response rate. Random forest (RF) models and clinical appraisal were used to select the variables to be balanced.

Results: 100 episodes of ISD prescription belonging to 73 patients were included in this analysis. In 32 episodes, patients were prescribed with CT (in 3 episodes CT was the initial therapeutic strategy; in 29, combination was the result to adding a second or third ISD). The most frequent drug used in MT was cyclosporine A (CYA; n=39), and the most frequent CT was synthetic + biological ISD (n=21). After RF, the number of previously used ISDs, the prescription of CYA, the dosage of oral corticosteroids at prescription, a previous ISD withdrawal due to inefficacy, and duration of disease were selected for balancing. In addition, after clinical appraisal, uveitis diagnosis, prescription with azathioprine, prescription with methotrexate, and eye activity features at prescription (presence of cells in anterior chamber, vitreous haze, macular edema, active chorioretinal lesions) were also balanced. The Energy balancing method showed the best balance for GTR. After Cox-regression, CT prescription did not show a statistically significant effect in the hazard of response (p=0.43; Table 1).

Conclusion: The use of CT in our study was not associated with a better therapeutic response in NIU patients compared with the prescription of MT. Considering that most CT episodes were the result of the addition of a new ISD in a patient already treated and still active, the effectiveness of CT as the initial therapeutic strategy remains unanswered.

Supporting image 1

Cox models showing the effect of combination therapy in the hazard of good therapeutic response after balancing covariates using the Energy method.


Disclosures: M. Álvarez Hernández, None; A. Madrid-García, None; A. Gómez Gómez, None; L. Borrego Sanz, None; R. Méndez Fernández, None; P. Arriola Villalobos, None; E. Pato Cour, None; D. Díaz Valle, None; L. Rodriguez-Rodriguez, None.

To cite this abstract in AMA style:

Álvarez Hernández M, Madrid-García A, Gómez Gómez A, Borrego Sanz L, Méndez Fernández R, Arriola Villalobos P, Pato Cour E, Díaz Valle D, Rodriguez-Rodriguez L. To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/to-combine-or-not-to-combine-influence-of-immunosuppressive-drug-combination-in-the-induction-of-therapeutic-response-in-non-infectious-uveitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/to-combine-or-not-to-combine-influence-of-immunosuppressive-drug-combination-in-the-induction-of-therapeutic-response-in-non-infectious-uveitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology